Catalyst Pharmaceuticals (CPRX) Cash & Current Investments (2010 - 2026)
Catalyst Pharmaceuticals (CPRX) posted Cash & Current Investments of $755.9 million for Q1 2026, up 6.58% on a QoQ basis from $709.2 million in Q4 2025, and up 30.17% year-over-year from $580.7 million in Q1 2025.
Catalyst Pharmaceuticals (CPRX) Cash & Current Investments (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $755.9 million for Q1 2026.
- Quarterly Cash & Current Investments rose 30.17% year-over-year to $755.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $755.9 million (up 30.17% YoY) and the FY2025 annual result came in at $709.2 million, up 37.02% from the prior year.
- Cash & Current Investments was $755.9 million for Q1 2026 at Catalyst Pharmaceuticals, up from $709.2 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $755.9 million in Q1 2026 and bottomed at $121.0 million in Q3 2023.
- A 5-year average of $387.8 million and a median of $310.4 million in 2024 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2023 — Cash & Current Investments plunged 53.87% — and 2024, when it jumped 276.03%.
- Catalyst Pharmaceuticals' Cash & Current Investments stood at $298.4 million in 2022, then plunged by 53.87% to $137.6 million in 2023, then soared by 276.03% to $517.6 million in 2024, then jumped by 37.02% to $709.2 million in 2025, then gained by 6.58% to $755.9 million in 2026.
- Business Quant data shows CPRX's Cash & Current Investments at $755.9 million in Q1 2026, $709.2 million in Q4 2025, and $689.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 755.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 755.86 Mn |
| Dec 31, 2025 | 709.17 Mn |
| Sep 30, 2025 | 689.89 Mn |
| Jun 30, 2025 | 652.80 Mn |
| Mar 31, 2025 | 580.66 Mn |
| Dec 31, 2024 | 517.55 Mn |
| Sep 30, 2024 | 442.33 Mn |
| Jun 30, 2024 | 375.69 Mn |
| Mar 31, 2024 | 310.41 Mn |
| Dec 31, 2023 | 137.64 Mn |
| Sep 30, 2023 | 120.97 Mn |
| Jun 30, 2023 | 178.79 Mn |
| Mar 31, 2023 | 148.25 Mn |
| Dec 31, 2022 | 298.40 Mn |
| Sep 30, 2022 | 256.07 Mn |
| Jun 30, 2022 | 220.79 Mn |
| Mar 31, 2022 | 197.80 Mn |
| Dec 31, 2021 | 191.27 Mn |
| Sep 30, 2021 | 174.79 Mn |
| Jun 30, 2021 | 155.28 Mn |